Atomo Diagnostics (ASX:AT1) 3-Year RORE % : -25.93% (As of Dec. 2025)


What is Atomo Diagnostics 3-Year RORE %?

Atomo Diagnostics ASX:AT1 3-Year RORE % is -25.93 as of Dec. 2025. The stock has 4 warning signs investors should review. Among 782 Medical Devices & Instruments companies, Atomo Diagnostics ranks worse than 70.59% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Atomo Diagnostics's 3-Year RORE % for the quarter that ended in Dec. 2025 was -25.93%.

The industry rank for Atomo Diagnostics's 3-Year RORE % or its related term are showing as below:

ASX:AT1's 3-Year RORE % is ranked worse than
70.59% of 782 companies
in the Medical Devices & Instruments industry
Industry Median: -4.23 vs ASX:AT1: -25.93

Atomo Diagnostics  (ASX:AT1) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Atomo Diagnostics 3-Year RORE % Related Terms


Atomo Diagnostics 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Atomo Diagnostics's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atomo Diagnostics 3-Year RORE % Chart

Atomo Diagnostics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
3-Year RORE %
Get a 7-Day Free Trial 0.00 0.00 15.79 2.63 -28.57

Atomo Diagnostics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.26 2.63 -15.79 -28.57 -25.93

ASX:AT1 vs ABT, SYK, MDT: 3-Year RORE % Comparison

For the Medical Devices subindustry, Atomo Diagnostics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atomo Diagnostics 3-Year RORE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Atomo Diagnostics's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Atomo Diagnostics's 3-Year RORE % falls into.



Atomo Diagnostics 3-Year RORE % Calculation

Atomo Diagnostics's 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.005--0.012 )/( -0.027-0 )
=0.007/-0.027
=-25.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -25.93 mean?
Atomo Diagnostics (ASX:AT1) has a 3-Year RORE % of -25.93 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Atomo Diagnostics and its competitors. According to the industry distribution chart, Atomo Diagnostics ranks #552 out of 782 companies in the Medical Devices & Instruments industry, placing it in the top 70.6%.
Is Atomo Diagnostics' 3-Year RORE % too high?
Atomo Diagnostics' current 3-Year RORE % is -25.93. Based on the distribution chart, Atomo Diagnostics ranks #552 out of 782 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does Atomo Diagnostics' 3-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Atomo Diagnostics ranks #552 out of 782 companies for 3-Year RORE %. This places Atomo Diagnostics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Atomo Diagnostics and its competitors. Atomo Diagnostics's current 3-Year RORE % is -25.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atomo Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Atomo Diagnostics (ASX:AT1) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.02 — trading 10% below its estimated fair value. The current 3-Year RORE % is -25.93. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Atomo Diagnostics (ASX:AT1), the current 3-Year RORE % is -25.93 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atomo Diagnostics Business Description

Address 3 - 5 George Street, Level 1, Leichhardt, Syndey, NSW, AUS, 2040
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.